查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1523275

恐懼症市場報告：2030 年趨勢、預測與競爭分析

Agoraphobia Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

恐懼症的趨勢與預測

預計到 2030 年，全球恐懼症市場規模將達到 15 億美元，2024 年至 2030 年複合年成長率為 6.3%。這個市場的主要驅動力是恐慌和焦慮症發病率的上升、對以患者為中心的個人化心理健康問題治療的需求不斷成長，以及虛擬實境暴露療法的接受度不斷提高。全球恐懼症市場的未來充滿希望，醫院、診所和學術機構市場充滿機會。

按細分領域分類的恐懼症

這項研究包括按藥物治療、療法、最終用途和地區對全球恐懼症的預測。

恐懼症市場洞察

由於 SSRI 有助於緩解與恐懼症相關的焦慮，並幫助患者更好地應對壓力情況，因此 Lucintel 預計選擇性血清素再回收抑制劑將在預測期內成為市場上最大的部分，我們預測這種情況將持續下去。

醫院仍然是該市場中最大的部分。

由於該地區人口恐懼症頻率不斷增加，在預測期內，北美仍將是最大的地區。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球恐懼症市場預計將達到 15 億美元。

Q2.市場成長預測是多少：

A2. 2024 年至 2030 年，全球恐懼症市場預計將以 6.3% 的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 這個市場的主要驅動力是恐慌和焦慮症發病率的上升、對以患者為中心的心理健康問題個性化治療的需求不斷成長以及對虛擬實境暴露療法的接受度不斷提高。

Q4.市場的主要細分市場是：

A4. 全球恐懼症市場前景廣闊，醫院、診所和學術機構市場充滿機會。

Q5.市場的主要企業是：

A5.主要恐懼症相關企業如下：

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Lundbeck
  • Takeda Pharmaceutical
  • Mylan Pharmaceuticals
  • Apotex

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計選擇性血清素再回收抑制劑在預測期內仍將是其最大的細分市場。這是因為 SSRI 可以幫助緩解與恐懼症相關的焦慮，並幫助患者更好地應對壓力情況。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於該地區人口廣場恐懼症的發生率不斷增加，北美在預測期內仍然是最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球恐懼症市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球恐懼症市場趨勢（2018-2023）與預測（2024-2030）
  • 按藥物治療分類的全球恐懼症市場
    • 選擇性血清素再回收抑制劑
    • 去甲腎上腺素再回收抑制劑
    • 抗焦慮藥
    • 其他
  • 按治療分類的全球恐懼症市場
    • 心理治療
    • 認知行為療法
    • 暴露療法
    • 其他
  • 以最終用途分類的全球恐懼症市場
    • 醫院
    • 診所
    • 學術機構
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 按地區分類的全球恐懼症市場
  • 北美恐懼症市場
  • 歐洲恐懼症市場
  • 亞太地區恐懼症市場
  • 其他區域恐懼症市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
  • 全球恐懼症市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球恐懼症市場的容量擴張
    • 全球恐懼症市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Lundbeck
  • Takeda Pharmaceutical
  • Mylan Pharmaceuticals
  • Apotex
簡介目錄

Agoraphobia Trends and Forecast

The future of the global agoraphobia market looks promising with opportunities in the hospital, clinic, and academic markets. The global agoraphobia market is expected to reach an estimated $1.5 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are rising rates of panic and anxiety disorders, growing need for patient-centered, individualized treatment for mental health issues, as well as, increasing acceptance of virtual reality exposure treatment.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Agoraphobia by Segment

The study includes a forecast for the global agoraphobia by drug treatment, therapy, end use, and region.

Agoraphobia Market by Drug Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Selective Serotonin Reuptake Inhibitor
  • Norepinephrine Reuptake Inhibitor
  • Anti-Anxiety Medication
  • Others

Agoraphobia Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Psychotherapy
  • Cognitive Behavioral Therapy
  • Exposure Therapy
  • Others

Agoraphobia Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital
  • Clinic
  • Academic
  • Others

Agoraphobia Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Agoraphobia Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies agoraphobia companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the agoraphobia companies profiled in this report include-

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Lundbeck
  • Takeda Pharmaceutical
  • Mylan Pharmaceuticals
  • Apotex

Agoraphobia Market Insights

Lucintel forecasts that selective serotonin reuptake inhibitor will remain the largest segment over the forecast period because SSRIs is useful in relieving anxiety associated with agoraphobia, assisting patients in better managing stressful circumstances.

Within this market, hospital will remain the largest segment.

North America will remain the largest region over the forecast period due to increase in the frequency of agoraphobia among the region's population.

Features of the Global Agoraphobia Market

Market Size Estimates: Agoraphobia market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Agoraphobia market size by drug treatment, therapy, end use, and region in terms of value ($B).

Regional Analysis: Agoraphobia market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug treatment, therapy, end use, and regions for the agoraphobia market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the agoraphobia market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the agoraphobia market size?

Answer: The global agoraphobia market is expected to reach an estimated $1.5 billion by 2030.

Q2. What is the growth forecast for agoraphobia market?

Answer: The global agoraphobia market is expected to grow with a CAGR of 6.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the agoraphobia market?

Answer: The major drivers for this market are rising rates of panic and anxiety disorders, growing need for patient-centered, individualized treatment for mental health issues, as well as, increasing acceptance of virtual reality exposure treatment.

Q4. What are the major segments for agoraphobia market?

Answer: The future of the global agoraphobia market looks promising with opportunities in the hospital, clinic, and academic markets.

Q5. Who are the key agoraphobia market companies?

Answer: Some of the key agoraphobia companies are as follows:

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Lundbeck
  • Takeda Pharmaceutical
  • Mylan Pharmaceuticals
  • Apotex

Q6. Which agoraphobia market segment will be the largest in future?

Answer: Lucintel forecasts that selective serotonin reuptake inhibitor will remain the largest segment over the forecast period because SSRIs is useful in relieving anxiety associated with agoraphobia, assisting patients in better managing stressful circumstances.

Q7. In agoraphobia market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increase in the frequency of agoraphobia among the region's population.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the agoraphobia market by drug treatment (selective serotonin reuptake inhibitor, norepinephrine reuptake inhibitor, anti-anxiety medication, and others), therapy (psychotherapy, cognitive behavioral therapy, exposure therapy, and others), end use (hospital, clinic, academic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Agoraphobia Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Agoraphobia Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Agoraphobia Market by Drug Treatment
    • 3.3.1: Selective Serotonin Reuptake Inhibitor
    • 3.3.2: Norepinephrine Reuptake Inhibitor
    • 3.3.3: Anti-Anxiety Medication
    • 3.3.4: Others
  • 3.4: Global Agoraphobia Market by Therapy
    • 3.4.1: Psychotherapy
    • 3.4.2: Cognitive Behavioral Therapy
    • 3.4.3: Exposure Therapy
    • 3.4.4: Others
  • 3.5: Global Agoraphobia Market by End Use
    • 3.5.1: Hospital
    • 3.5.2: Clinic
    • 3.5.3: Academic
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Agoraphobia Market by Region
  • 4.2: North American Agoraphobia Market
    • 4.2.1: North American Agoraphobia Market by Drug Treatment: Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication, and Others
    • 4.2.2: North American Agoraphobia Market by End Use: Hospital, Clinic, Academic, and Others
  • 4.3: European Agoraphobia Market
    • 4.3.1: European Agoraphobia Market by Drug Treatment: Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication, and Others
    • 4.3.2: European Agoraphobia Market by End Use: Hospital, Clinic, Academic, and Others
  • 4.4: APAC Agoraphobia Market
    • 4.4.1: APAC Agoraphobia Market by Drug Treatment: Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication, and Others
    • 4.4.2: APAC Agoraphobia Market by End Use: Hospital, Clinic, Academic, and Others
  • 4.5: ROW Agoraphobia Market
    • 4.5.1: ROW Agoraphobia Market by Drug Treatment: Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication, and Others
    • 4.5.2: ROW Agoraphobia Market by End Use: Hospital, Clinic, Academic, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Agoraphobia Market by Drug Treatment
    • 6.1.2: Growth Opportunities for the Global Agoraphobia Market by Therapy
    • 6.1.3: Growth Opportunities for the Global Agoraphobia Market by End Use
    • 6.1.4: Growth Opportunities for the Global Agoraphobia Market by Region
  • 6.2: Emerging Trends in the Global Agoraphobia Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Agoraphobia Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Agoraphobia Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Eli Lilly and Company
  • 7.2: GlaxoSmithKline
  • 7.3: Pfizer
  • 7.4: AstraZeneca
  • 7.5: Bristol-Myers Squibb Company
  • 7.6: Johnson & Johnson
  • 7.7: Lundbeck
  • 7.8: Takeda Pharmaceutical
  • 7.9: Mylan Pharmaceuticals
  • 7.10: Apotex